Zoetis Q4 revenue rises 3%, beats analyst expectations

Reuters02-12 20:07
Zoetis Q4 revenue rises 3%, beats analyst expectations

Overview

  • Animal health firm's Q4 revenue rose 3%, beating analyst expectations

  • Adjusted EPS for Q4 beat analyst expectations

  • Company advanced OA pain franchise with new product approvals in Canada and EU

Outlook

  • Zoetis provides full-year 2026 revenue guidance of $9.825 bln to $10.025 bln

  • Company expects 3% to 5% organic operational growth in revenue for 2026

  • Zoetis forecasts adjusted diluted EPS of $7.00 to $7.10 for full year 2026

Result Drivers

  • U.S. SEGMENT - Revenue decreased 2% due to lower sales of monoclonal antibody products, offset by growth in parasiticides

  • INTERNATIONAL SEGMENT - Revenue increased 8%, driven by parasiticides and dermatology products

  • FISCAL YEAR ALIGNMENT - Operational changes contributed to revenue growth in the International segment

Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q4 Revenue

Beat

$2.39 bln

$2.36 bln (13 Analysts)

Q4 Adjusted EPS

Beat

$1.48

$1.40 (15 Analysts)

Q4 EPS

$1.37

Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 13 "strong buy" or "buy", 7 "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the pharmaceuticals peer group is "buy"

  • Wall Street's median 12-month price target for Zoetis Inc is $156.44, about 21.6% above its February 11 closing price of $128.67

  • The stock recently traded at 19 times the next 12-month earnings vs. a P/E of 21 three months ago

Press Release: ID:nBwcc1YSna

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment